QQQ   285.33 (+0.52%)
AAPL   144.96 (+1.62%)
MSFT   247.37 (-0.01%)
META   116.80 (+1.27%)
GOOGL   93.91 (+0.21%)
AMZN   89.63 (-0.80%)
TSLA   181.74 (+4.79%)
NVDA   175.09 (+1.98%)
NIO   13.01 (-2.98%)
BABA   92.74 (-1.52%)
AMD   70.44 (-0.04%)
T   19.33 (+1.10%)
MU   55.84 (+1.16%)
CGC   3.00 (-2.91%)
F   13.35 (+1.75%)
GE   82.73 (-1.08%)
DIS   94.69 (+2.31%)
AMC   5.99 (-1.32%)
PYPL   74.32 (+0.13%)
PFE   51.96 (+0.35%)
NFLX   328.26 (+5.80%)
QQQ   285.33 (+0.52%)
AAPL   144.96 (+1.62%)
MSFT   247.37 (-0.01%)
META   116.80 (+1.27%)
GOOGL   93.91 (+0.21%)
AMZN   89.63 (-0.80%)
TSLA   181.74 (+4.79%)
NVDA   175.09 (+1.98%)
NIO   13.01 (-2.98%)
BABA   92.74 (-1.52%)
AMD   70.44 (-0.04%)
T   19.33 (+1.10%)
MU   55.84 (+1.16%)
CGC   3.00 (-2.91%)
F   13.35 (+1.75%)
GE   82.73 (-1.08%)
DIS   94.69 (+2.31%)
AMC   5.99 (-1.32%)
PYPL   74.32 (+0.13%)
PFE   51.96 (+0.35%)
NFLX   328.26 (+5.80%)
QQQ   285.33 (+0.52%)
AAPL   144.96 (+1.62%)
MSFT   247.37 (-0.01%)
META   116.80 (+1.27%)
GOOGL   93.91 (+0.21%)
AMZN   89.63 (-0.80%)
TSLA   181.74 (+4.79%)
NVDA   175.09 (+1.98%)
NIO   13.01 (-2.98%)
BABA   92.74 (-1.52%)
AMD   70.44 (-0.04%)
T   19.33 (+1.10%)
MU   55.84 (+1.16%)
CGC   3.00 (-2.91%)
F   13.35 (+1.75%)
GE   82.73 (-1.08%)
DIS   94.69 (+2.31%)
AMC   5.99 (-1.32%)
PYPL   74.32 (+0.13%)
PFE   51.96 (+0.35%)
NFLX   328.26 (+5.80%)
QQQ   285.33 (+0.52%)
AAPL   144.96 (+1.62%)
MSFT   247.37 (-0.01%)
META   116.80 (+1.27%)
GOOGL   93.91 (+0.21%)
AMZN   89.63 (-0.80%)
TSLA   181.74 (+4.79%)
NVDA   175.09 (+1.98%)
NIO   13.01 (-2.98%)
BABA   92.74 (-1.52%)
AMD   70.44 (-0.04%)
T   19.33 (+1.10%)
MU   55.84 (+1.16%)
CGC   3.00 (-2.91%)
F   13.35 (+1.75%)
GE   82.73 (-1.08%)
DIS   94.69 (+2.31%)
AMC   5.99 (-1.32%)
PYPL   74.32 (+0.13%)
PFE   51.96 (+0.35%)
NFLX   328.26 (+5.80%)
NASDAQ:UBX

Unity Biotechnology - UBX Stock Forecast, Price & News

$2.99
+0.14 (+4.91%)
(As of 12/9/2022 11:43 AM ET)
Add
Compare
Today's Range
$2.85
$2.99
50-Day Range
$2.12
$30.90
52-Week Range
$2.09
$20.00
Volume
608 shs
Average Volume
276,635 shs
Market Capitalization
$42.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.40

Unity Biotechnology MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,149.1% Upside
$35.60 Price Target
Short Interest
Bearish
6.49% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.60
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$14,460 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.90) to ($4.77) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.93 out of 5 stars

Medical Sector

681st out of 1,022 stocks

Pharmaceutical Preparations Industry

325th out of 499 stocks

UBX stock logo

About Unity Biotechnology (NASDAQ:UBX) Stock

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

Receive UBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Unity Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

UBX Stock News Headlines

H.C. Wainwright Keeps Their Buy Rating on Unity Biotechnology (UBX)
UNITY Biotechnology Inc
See More Headlines
Receive UBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Unity Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

UBX Company Calendar

Last Earnings
11/08/2022
Today
12/09/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/21/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:UBX
Fax
N/A
Employees
65
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$35.60
High Stock Price Forecast
$80.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+1,117.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-60,720,000.00
Pretax Margin
-1,124.56%

Debt

Sales & Book Value

Annual Sales
$4.78 million
Book Value
$10.32 per share

Miscellaneous

Free Float
13,681,000
Market Cap
$42.43 million
Optionable
Not Optionable
Beta
0.62

Key Executives

  • Dr. Anirvan Ghosh Ph.D. (Age 58)
    CEO & Director
    Comp: $885.54k
  • Dr. Nathaniel E. David A.B. (Age 54)
    Ph.D., Co-Founder & Exec. Director
    Comp: $40k
  • Ms. Lynne Marie Sullivan (Age 55)
    CFO & Head of Corp. Devel.
    Comp: $614.84k
  • Dr. Jamie Dananberg M.D. (Age 64)
    Chief Medical Officer
    Comp: $635.79k
  • Dr. Jan M. van Deursen
    Founder
  • Dr. Judith Campisi Ph.D.
    Founder
  • Mr. Daohong Zhou M.D.
    Founder
  • Mr. Nathan Guz Ph.D.
    VP of Operations
  • Mr. Alexander Azoy (Age 46)
    VP of Fin., Chief Accounting Officer, Controller & Principal Accounting Officer
  • Dr. Przemyslaw Sapieha Ph.D.
    Chief Scientific Advisor













UBX Stock - Frequently Asked Questions

Should I buy or sell Unity Biotechnology stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" UBX shares.
View UBX analyst ratings
or view top-rated stocks.

What is Unity Biotechnology's stock price forecast for 2023?

6 Wall Street research analysts have issued twelve-month target prices for Unity Biotechnology's stock. Their UBX share price forecasts range from $10.00 to $80.00. On average, they anticipate the company's stock price to reach $35.60 in the next year. This suggests a possible upside of 1,149.1% from the stock's current price.
View analysts price targets for UBX
or view top-rated stocks among Wall Street analysts.

How have UBX shares performed in 2022?

Unity Biotechnology's stock was trading at $14.60 on January 1st, 2022. Since then, UBX shares have decreased by 80.5% and is now trading at $2.85.
View the best growth stocks for 2022 here
.

Are investors shorting Unity Biotechnology?

Unity Biotechnology saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 820,100 shares, an increase of 333.2% from the October 31st total of 189,300 shares. Based on an average daily volume of 691,600 shares, the days-to-cover ratio is presently 1.2 days. Currently, 6.5% of the company's stock are short sold.
View Unity Biotechnology's Short Interest
.

When is Unity Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 21st 2023.
View our UBX earnings forecast
.

How were Unity Biotechnology's earnings last quarter?

Unity Biotechnology, Inc. (NASDAQ:UBX) announced its quarterly earnings data on Tuesday, November, 8th. The company reported ($1.36) earnings per share for the quarter, missing the consensus estimate of ($0.99) by $0.37.

When did Unity Biotechnology's stock split?

Unity Biotechnology shares reverse split before market open on Thursday, October 20th 2022. The 1-10 reverse split was announced on Thursday, October 20th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Unity Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Unity Biotechnology investors own include NIO (NIO), Inseego (INSG), NVIDIA (NVDA), Editas Medicine (EDIT), Advanced Micro Devices (AMD), VBI Vaccines (VBIV), Enphase Energy (ENPH), Sorrento Therapeutics (SRNE) and OPKO Health (OPK).

When did Unity Biotechnology IPO?

(UBX) raised $85 million in an initial public offering on Thursday, May 3rd 2018. The company issued 5,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup acted as the underwriters for the IPO and Mizuho Securities was co-manager.

What is Unity Biotechnology's stock symbol?

Unity Biotechnology trades on the NASDAQ under the ticker symbol "UBX."

Who are Unity Biotechnology's major shareholders?

Unity Biotechnology's stock is owned by a number of retail and institutional investors. Top institutional investors include ARCH Venture Management LLC (75.06%), Vanguard Group Inc. (31.27%), Empery Asset Management LP (31.09%), Altium Capital Management LP (30.09%), 683 Capital Management LLC (19.89%) and Renaissance Technologies LLC (11.15%). Insiders that own company stock include Anirvan Ghosh, Jamie Dananberg and Nathaniel E David.
View institutional ownership trends
.

How do I buy shares of Unity Biotechnology?

Shares of UBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Unity Biotechnology's stock price today?

One share of UBX stock can currently be purchased for approximately $2.85.

How much money does Unity Biotechnology make?

Unity Biotechnology (NASDAQ:UBX) has a market capitalization of $40.45 million and generates $4.78 million in revenue each year. The company earns $-60,720,000.00 in net income (profit) each year or ($7.86) on an earnings per share basis.

How can I contact Unity Biotechnology?

The official website for the company is www.unitybiotechnology.com. The company can be reached via phone at (650) 416-1192 or via email at ir@unitybiotechnology.com.

This page (NASDAQ:UBX) was last updated on 12/9/2022 by MarketBeat.com Staff